drugset
drugset / Trial / NCT01088763

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

NCT01088763 ↗

Phase 1 Terminated 129 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2010-03
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject RG4733 Small molecule — Oral
Background Dexamethasone Small molecule — Intravenous

Indications

Burkitt lymphoma Hodgkins lymphoma T-cell childhood acute lymphocytic leukemia T-cell large granular lymphocyte leukemia TSH-secreting pituitary adenoma anaplastic large cell lymphoma atypical teratoid rhabdoid tumor benign meningioma central nervous system teratoma childhood brain stem glioma childhood central nervous system germinoma childhood central nervous system mixed germ cell tumor childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma childhood oligodendroglioma childhood spinal cord tumor chromophobe adenoma craniopharyngioma ependymoblastoma grade II meningioma grade III lymphomatoid granulomatosis grade III meningioma medulloepithelioma mixed glioma optic pathway glioma pediatric CNS choriocarcinoma pediatric infratentorial ependymoma pediatric supratentorial ependymoma pineoblastoma pituitary gland acidophil adenoma pituitary gland basophil adenoma prolactin-producing pituitary gland adenoma subependymal giant cell astrocytoma supratentorial primitive neuroectodermal tumor yolk sac tumor of central nervous system